A compound of formula (I):
or, where appropriate, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof
wherein
A represents >C=X, wherein
X represents oxygen or sulphur, or A represents a bond;
Y represents N or N⁺-O⁻ or a moiety CR₈,
and the other substituents are defined as in claim 1;
a process for the preparation of such a compound, a pharmaceutical composition comprising such a compound and the use of such a compound and composition in medicine.
BUCKLE, DEREK R.;ARCH, JONATHAN R. S.;EDGE, COLIN;FOSTER, KEITH A.;HOUGE-+, J. MED. CHEM., 34,(1991) N, C. 919-926
作者:BUCKLE, DEREK R.、ARCH, JONATHAN R. S.、EDGE, COLIN、FOSTER, KEITH A.、HOUGE-+
DOI:——
日期:——
Synthesis and smooth muscle relaxant activity of a new series of potassium channel activators: 3-amido-1,1-dimethylindan-2-ols
作者:Derek R. Buckle、Jonathan R. S. Arch、Colin Edge、Keith A. Foster、Catherine S. V. Houge-Frydrych、Ivan L. Pinto、David G. Smith、John F. Taylor、Stephen G. Taylor
DOI:10.1021/jm00107a008
日期:1991.3
The synthesis of a novel series of smoothmusclerelaxants which have been shown to act via the opening or activation of potassium channels is described. Compounds have been evaluated for their ability to inhibit spontaneous tone in guinea pig isolated trachealis and structure-activityrelationships are discussed. One compound in particular, 1,1-dimethyl-5-nitro-3-(2-pyridon-1-yl)indan-2-ol, (16) was